AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14552594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% brimonidine eye drops given twice daily for 30 days
Number of subjects: 16
Study 14552594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 16
Study 10975179 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance monitoring
Number of subjects: 0
Study 10975179 — intervention group
Group type: EXPERIMENTAL
Intervention: Team self‐correction
Number of subjects: 0
Study 9123927 — intervention group
Group type: EXPERIMENTAL
Intervention: Neocyte transfusion
Number of subjects: 18
Study 9123927 — intervention group
Group type: COMPARATOR
Intervention: Standard red cell transfusion
Number of subjects: 18
Study 1613672 — intervention group
Group type: EXPERIMENTAL
Intervention: VaxSyn HIV-1
Number of subjects: 12
Study 1613672 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 12
Study 1613672 — intervention group
Group type: COMPARATOR
Intervention: Alum adjuvant
Number of subjects: 12
Study 382906 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0
Study 382906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31967736 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen combination material (collagen cone and collagen membrane)
Number of subjects: 10
Study 31967736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study 31753009 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg nicotine gum
Number of subjects: 240
Study 31753009 — intervention group
Group type: COMPARATOR
Intervention: 4 mg nicotine gum
Number of subjects: 240
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5mg qd
Number of subjects: 733
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 500mg bid
Number of subjects: 733
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin 1000mg bid
Number of subjects: 733
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 500mg bid
Number of subjects: 733
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 1000mg bid
Number of subjects: 733
Study 28088030 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 2.5mg/metformin 1000mg bid (severe hyperglycemia group)
Number of subjects: 733
Study 28088030 — intervention group
Group type: COMPARATOR
Intervention: linagliptin 5mg qd (severe hyperglycemia group)
Number of subjects: 733
Study 25414262 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-IVM1 (AL plus single dose of ivermectin 200 µg/kg)
Number of subjects: 120
Study 25414262 — intervention group
Group type: EXPERIMENTAL
Intervention: AL-IVM2 (AL plus repeated dose of ivermectin 200 µg/kg)
Number of subjects: 120
Study 25414262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (AL plus placebo)
Number of subjects: 120
Study 25414262 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM (Ivermectin)
Number of subjects: 120
Study 23552714 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 206
Study 23552714 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 206
Study 23552714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study 21809664 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemo-infusion with oxaliplatin (FOLFOX)
Number of subjects: 162
Study 21809664 — intervention group
Group type: COMPARATOR
Intervention: Regional chemo-infusion with irinotecan (FOLFIRI)
Number of subjects: 162
Study 21809664 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemo-infusion
Number of subjects: 162
Study 21809664 — intervention group
Group type: COMPARATOR
Intervention: Regional chemo-infusion
Number of subjects: 162
Study 21809664 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 162
Study 19728751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg once daily for 10 days followed by 10 mg once daily for 10 days, along with aspirin 75 mg daily
Number of subjects: 32
Study 19728751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg maintenance dosing
Number of subjects: 32
Study 19728751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg maintenance dosing
Number of subjects: 32
Study 16961674 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific anticoagulant prescription forms
Number of subjects: 1469
Study 16961674 — intervention group
Group type: COMPARATOR
Intervention: Usual prescribing practices (Control)
Number of subjects: 1469
Study 16146551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 8-12 ng/mL (GI)
Number of subjects: 70
Study 16146551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 15 mg loading dose followed by 5 mg fixed doses, maintaining trough concentrations of 15-20 ng/mL (GII)
Number of subjects: 70
Study 12966414 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 200 mg/m² i.v. (1-h infusion) on day 1, L-leucovorin 250 mg/m² i.v. (1-h infusion) plus 5-fluorouracil 850 mg/m² i.v. bolus on day 2 every 2 weeks (IRIFAFU)
Number of subjects: 108
Study 12966414 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 108
Study 10218721 — intervention group
Group type: EXPERIMENTAL
Intervention: Temocapril 20 mg daily (n = 19)
Number of subjects: 30
Study 10218721 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 30
Study 7611316 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity between 20/50 and 20/80
Number of subjects: 35
Study 7611316 — intervention group
Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity between 20/25 and 20/40
Number of subjects: 35
Study 2095610 — intervention group
Group type: EXPERIMENTAL
Intervention: butamirate citrate linctus (Sinecod, Zyma)
Number of subjects: 60
Study 2095610 — intervention group
Group type: COMPARATOR
Intervention: clobutinol syrup (Silomat, Boehringer, Ingelheim)
Number of subjects: 60
Study 508075 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional feedback stimulation training (PFST) in addition to conventional treatment
Number of subjects: 30
Study 508075 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study 31591187 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor palbociclib and fulvestrant
Number of subjects: 210
Study 31591187 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of NF1
Number of subjects: 210
Study 31591187 — intervention group
Group type: EXPERIMENTAL
Intervention: NF1 mutations
Number of subjects: 210
Study 31591187 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 210
Study 31591187 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2, AKT1, NF1 mutations
Number of subjects: 210
Study 29641247 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsella bursa‐pastoris capsules (dosage: 2 capsules every 12 hours)
Number of subjects: 84
Study 29641247 — intervention group
Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg, dosage: 2 capsules every 8 hours) + placebo
Number of subjects: 84
Study 29207980 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavior therapy (CaCBTp), 12 weekly sessions
Number of subjects: 36
Study 29207980 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 36
Study 29207980 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavior therapy (CaCBTp)
Number of subjects: 36
Study 26255892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime and amoxicillin/clavulanic acid combination therapy
Number of subjects: 51
Study 26255892 — intervention group
Group type: COMPARATOR
Intervention: Tigecycline-based therapy
Number of subjects: 51
Study 24079038 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (50 f.Lg Bid)
Number of subjects: 30
Study 24079038 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate (50 f.Lg Bid) and Totropiumi (18 f.Lg Qd)
Number of subjects: 30
Study 24079038 — intervention group
Group type: COMPARATOR
Intervention: Control group (Single group)
Number of subjects: 30
Study 20417012 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional (3D) miniplate fixation
Number of subjects: 20
Study 20417012 — intervention group
Group type: COMPARATOR
Intervention: Champy's miniplate fixation
Number of subjects: 20
Study 18818386 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA; n = 22)
Number of subjects: 52
Study 18818386 — intervention group
Group type: COMPARATOR
Intervention: Successful Aging health educational control (SA; n = 20)
Number of subjects: 52
Study 15990739 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular implantation of a Medtronic Talent stent graft adjunctive to best medical treatment
Number of subjects: 136
Study 15990739 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment alone
Number of subjects: 136
Study 12551865 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (600 mg single oral dose)
Number of subjects: 14
Study 12551865 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy non-smokers)
Number of subjects: 14
Study 12551865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 14
Study 10097929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix25 insulin (36 ± 4 U)
Number of subjects: 22
Study 10097929 — intervention group
Group type: COMPARATOR
Intervention: 30/70 insulin
Number of subjects: 22
Study 10097929 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 22
Study 8906292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MAOIs-A/B with 5-HTP
Number of subjects: 0
Study 8906292 — intervention group
Group type: COMPARATOR
Intervention: 5-HTP alone
Number of subjects: 0
Study 8906292 — intervention group
Group type: COMPARATOR
Intervention: MAOIs-A/B alone
Number of subjects: 0
Study 8906292 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 1867971 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotic prophylaxis
Number of subjects: 138
Study 1867971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 138
Study 7133792 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange
Number of subjects: 94
Study 7133792 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 94
Study 31165606 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone group (6-month home-based phone surveillance program with 12 scheduled phone calls every fortnight)
Number of subjects: 84
Study 31165606 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone group (6-month home-based phone surveillance program)
Number of subjects: 84
Study 31088188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg/day
Number of subjects: 477
Study 31088188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 24464328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 0
Study 24464328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25050518 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (1,500 mg/day in 3 divided doses; n=19)
Number of subjects: 40
Study 25050518 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=21)
Number of subjects: 40
Study 25050518 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Curcuminoids and Placebo
Number of subjects: 40
Study 24447437 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-valent pneumococcal conjugate vaccine (PCV-7)
Number of subjects: 200
Study 24447437 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 200
Study 22933671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular viscoseal instillation (13 men and 3 women)
Number of subjects: 32
Study 22933671 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic ACL reconstruction alone (15 men and 1 woman)
Number of subjects: 32
Study 22933671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular viscoseal instillation
Number of subjects: 32
Study 19567453 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 476
Study 19567453 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 476
Study 18604047 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg/kg)
Number of subjects: 90
Study 18604047 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg)
Number of subjects: 90
Study 18604047 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (placebo)
Number of subjects: 90
Study 15028356 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior fat pad preservation (group A)
Number of subjects: 55
Study 15028356 — intervention group
Group type: COMPARATOR
Intervention: Anterior fat pad dissection (group B)
Number of subjects: 55
Study 10932030 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 635
Study 10932030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 9048390 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 437
Study 9048390 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (Control)
Number of subjects: 437
Study 8342183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycerol (500 mL of 10% glycerol in saline over 4 hours on 6 consecutive days)
Number of subjects: 113
Study 8342183 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (saline)
Number of subjects: 113
Study 8342183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 113
Study 8342183 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 113
Study 3730726 — intervention group
Group type: EXPERIMENTAL
Intervention: Axis-to-axis extrapolation
Number of subjects: 32
Study 3730726 — intervention group
Group type: EXPERIMENTAL
Intervention: Line-to-axis extrapolation
Number of subjects: 32
Study 3730726 — intervention group
Group type: EXPERIMENTAL
Intervention: Axis-to-line extrapolation
Number of subjects: 32
Study 3730726 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children (nine-year-olds)
Number of subjects: 32
Study 3730726 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-perpendicular lines
Number of subjects: 32
Study 30475014 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (adaptive) training
Number of subjects: 110
Study 30475014 — intervention group
Group type: COMPARATOR
Intervention: Control (nonadaptive) training
Number of subjects: 110
Study 27716979 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with connective tissue graft
Number of subjects: 40
Study 27716979 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified microsurgical tunnel technique (MMTT) with connective tissue graft
Number of subjects: 40
Study 25028357 — intervention group
Group type: COMPARATOR
Intervention: IVB (1.25 mg)
Number of subjects: 52
Study 25028357 — intervention group
Group type: EXPERIMENTAL
Intervention: IVB+TRP (1.25 mg IVB combined with targeted retinal photocoagulation)
Number of subjects: 52
Study 23084240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 0.5 mg monthly (0.5q4)
Number of subjects: 2419
Study 23084240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg monthly (2q4)
Number of subjects: 2419
Study 23084240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 2 months after 3 initial monthly doses (2q8)
Number of subjects: 2419
Study 23084240 — intervention group
Group type: COMPARATOR
Intervention: Monthly ranibizumab 0.5 mg (Rq4)
Number of subjects: 2419
Study 23084240 — intervention group
Group type: EXPERIMENTAL
Intervention: All aflibercept regimens
Number of subjects: 2419
Study 23084240 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2419
Study 20737113 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming group (n = 30)
Number of subjects: 61
Study 20737113 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 61
Study 18670833 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion-oriented messages
Number of subjects: 518
Study 18670833 — intervention group
Group type: COMPARATOR
Intervention: Prevention-oriented messages
Number of subjects: 518
Study 15770890 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 15770890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and combined chemoradiation
Number of subjects: 0
Study 15770890 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combined chemotherapy regimens, monoclonal antibodies, radiolabeled antibodies, and bone marrow or stem cell transplantation
Number of subjects: 0
Study 15770890 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccines, antisense therapy, and proteasome inhibitors
Number of subjects: 0
Study 12579101 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid (bolus of 40 U/kg)
Number of subjects: 71
Study 12579101 — intervention group
Group type: COMPARATOR
Intervention: Heparin (bolus of 1 mg/kg)
Number of subjects: 71
Study 11057100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pokeweed (PWM) stimulation
Number of subjects: 102
Study 11057100 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin (PHA) stimulation
Number of subjects: 102
Study 7590048 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial flexible sigmoidoscopy plus air-contrast barium enema
Number of subjects: 149
Study 7590048 — intervention group
Group type: COMPARATOR
Intervention: Initial colonoscopy
Number of subjects: 149
Study 2177507 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interferon and/or podophyllin treatment
Number of subjects: 37
Study 2177507 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin and/or interferon
Number of subjects: 37
Study 6996816 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg BID cephradine
Number of subjects: 130
Study 6996816 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg BID cephradine
Number of subjects: 130
Study 30628167 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (10 g d-1)
Number of subjects: 296
Study 30628167 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain (25 g d-1)
Number of subjects: 296
Study 30628167 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuts (30 g d-1)
Number of subjects: 296
Study 30628167 — intervention group
Group type: EXPERIMENTAL
Intervention: Legumes (25 g d-1)
Number of subjects: 296
Study 30628167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (25 g d-1)
Number of subjects: 296
Study 29580529 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded sorghum breakfast cereal combined with unfermented probiotic milk
Number of subjects: 0
Study 27216350 — intervention group
Group type: EXPERIMENTAL
Intervention: oxymetazoline plus mometasone furoate nasal spray (MFNS)
Number of subjects: 68
Study 27216350 — intervention group
Group type: COMPARATOR
Intervention: placebo plus mometasone furoate nasal spray (MFNS)
Number of subjects: 68
Study 25109411 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 extensive metabolizers
Number of subjects: 24
Study 25109411 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 C3435T polymorphisms (C/C, C/T, T/T)
Number of subjects: 24
Study 22566413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling for mothers on breastfeeding and complementary feeding during the first year of infants' lives (n = 200)
Number of subjects: 500
Study 22566413 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 300)
Number of subjects: 500
Study 22566413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling for mothers (n = 200)
Number of subjects: 500
Study 20485306 — intervention group
Group type: EXPERIMENTAL
Intervention: L4 diet (63.3% SFA/4.06% R-TFA)
Number of subjects: 111
Study 20485306 — intervention group
Group type: COMPARATOR
Intervention: L0 diet (72% SFA/2.85% R-TFA)
Number of subjects: 111
Study 17083910 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mm² Baerveldt glaucoma implant
Number of subjects: 212
Study 17083910 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with mitomycin C (MMC)
Number of subjects: 212
Study 16097647 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide cisternography with early bladder visualization and blood activity monitoring
Number of subjects: 9
Study 16097647 — intervention group
Group type: COMPARATOR
Intervention: Normal pressure hydrocephalus (NPH) as control
Number of subjects: 9
Study 16097647 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood radioactivity monitoring
Number of subjects: 9
Study 12092940 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific sexual health intervention
Number of subjects: 218
Study 12092940 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 218
Study 9654221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (400 msec cycle length, extrastimulus delivered once)
Number of subjects: 30
Study 9654221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (400 msec cycle length, extrastimulus repeated three times)
Number of subjects: 30
Study 9654221 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (300 msec cycle length, no repetition of extrastimuli)
Number of subjects: 30
Study 9654221 — intervention group
Group type: COMPARATOR
Intervention: All protocols
Number of subjects: 30
Study 7615107 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 7.5 mg/d for 9 months
Number of subjects: 18
Study 7615107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2385206 — intervention group
Group type: EXPERIMENTAL
Intervention: Golytely
Number of subjects: 28
Study 2385206 — intervention group
Group type: COMPARATOR
Intervention: Cascara-Salax
Number of subjects: 28